AKBA
Akebia Therapeutics, Inc. NASDAQ Listed Mar 20, 2014$1.07
+4.90%
vs $1.02
Mkt Cap $275.2M
52w Low $0.87
6.3% of range
52w High $4.01
50d MA $1.18
200d MA $1.71
P/E (TTM)
—
EV/EBITDA
—
P/B
8.4x
Debt/Equity
6.6x
ROE
-16.4%
P/FCF
4.0x
RSI (14)
56.10
ATR (14)
$0.07
Beta
0.37
50d MA
$1.18
200d MA
$1.71
Avg Volume
6.4M
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
245 First Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 1.48 | -23.0% | -20.3% | -1.7% | -0.9% | +2.6% | +0.0% | — |
| Feb 26, 2026 | AMC | -0.03 | -0.05 | -66.7% | 1.32 | -1.5% | -0.8% | -3.8% | -3.2% | +2.5% | -4.8% | — |
| Nov 10, 2025 | AMC | -0.06 | 0.00 | +103.3% | 1.67 | +0.6% | +8.4% | +2.2% | -4.9% | -5.1% | +5.4% | — |
| Aug 7, 2025 | AMC | -0.02 | 0.00 | +104.5% | 3.01 | +1.7% | +13.6% | -2.0% | -0.9% | -0.6% | -0.3% | — |
| May 8, 2025 | AMC | -0.03 | 0.03 | +200.0% | 2.62 | +0.0% | -2.7% | -4.7% | +2.1% | -1.2% | +3.7% | — |
| Mar 13, 2025 | AMC | -0.05 | -0.10 | -100.0% | 1.69 | +4.7% | +33.7% | +6.2% | +6.2% | +11.4% | -28.2% | — |
| Nov 7, 2024 | AMC | -0.05 | -0.10 | -100.0% | 1.87 | -1.6% | +3.7% | +2.6% | -2.0% | -1.5% | -3.1% | — |
| Aug 8, 2024 | AMC | -0.06 | -0.04 | +33.3% | 1.19 | +0.0% | -6.7% | +10.8% | +8.9% | +0.7% | +6.7% | — |
| May 9, 2024 | AMC | -0.09 | -0.09 | +0.0% | 1.33 | -6.0% | -9.0% | +6.6% | -4.7% | -4.1% | -3.4% | — |
| Mar 14, 2024 | AMC | 0.00 | 0.00 | +99.4% | 1.37 | +16.8% | +24.1% | +11.2% | -3.2% | +6.0% | +5.2% | — |
| Nov 8, 2023 | AMC | -0.09 | -0.08 | +11.1% | 0.96 | +1.0% | -5.2% | -1.9% | +3.4% | +11.6% | -2.9% | — |
| Aug 25, 2023 | AMC | -0.03 | -0.06 | -140.0% | 1.15 | +7.0% | +20.0% | +11.6% | -9.1% | -0.7% | -4.3% | — |
| May 8, 2023 | AMC | -0.15 | -0.14 | +6.7% | 1.06 | -3.8% | -0.9% | -1.9% | +2.9% | +6.6% | -3.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | BTIG | Maintains | Buy → Buy | — | $1.32 | $1.32 | +0.0% | +4.5% | +3.6% | -1.4% | -0.7% | +5.0% |
| Feb 25 | BTIG | Maintains | Buy → Buy | — | $1.24 | $1.25 | +0.8% | -2.4% | +9.1% | -0.8% | -3.8% | -3.2% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.38 | $1.36 | -1.4% | +0.7% | +7.9% | +0.7% | +2.6% | -12.3% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.36 | -1.4% | +0.7% | +7.9% | +0.7% | +2.6% | -12.3% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | -2.6% | +6.8% | +1.3% | -3.1% | +5.2% |
| Dec 2 | BTIG | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | -2.6% | +6.8% | +1.3% | -3.1% | +5.2% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.10 | $2.09 | -0.5% | +0.0% | +5.2% | -4.1% | -1.4% | +1.4% |
| Oct 29 | BTIG | Maintains | Buy → Buy | — | $3.09 | $2.16 | -30.1% | -32.0% | +0.0% | +5.2% | -4.1% | -1.4% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.88 | $1.83 | -2.7% | -5.9% | +0.0% | -5.1% | +1.2% | -8.8% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.69 | $1.77 | +4.7% | +33.7% | +6.2% | +6.2% | +11.4% | -28.2% |
| Mar 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.69 | $1.77 | +4.7% | +33.7% | +6.2% | +6.2% | +11.4% | -28.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.38 | -0.4% | +0.0% | -0.4% | -3.4% | -0.4% | +0.4% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.90 | +1.6% | +1.1% | +2.6% | -0.5% | +7.3% | +14.5% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.64 | $1.69 | +3.0% | -3.0% | -0.6% | +0.6% | +2.5% | +4.9% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.28 | $1.28 | +0.0% | +0.0% | +3.1% | +0.0% | -0.8% | +1.5% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.30 | -1.5% | +0.0% | -3.0% | +0.0% | +3.1% | +0.0% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.39 | +0.7% | -2.2% | +5.2% | +4.2% | -2.7% | +0.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.11 | $1.17 | +5.4% | +10.8% | +8.9% | +0.7% | +6.7% | +0.0% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.24 | $2.47 | +10.3% | -18.3% | -10.9% | -3.1% | -5.7% | +1.3% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.37 | $1.60 | +16.8% | +24.1% | +11.2% | -3.2% | +6.0% | +5.2% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.99 | $1.02 | +3.1% | +1.1% | +2.0% | -3.4% | +0.5% | +1.0% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.17 | $1.21 | +3.4% | -1.7% | -2.6% | +1.8% | +0.9% | -8.7% |
| Aug 28 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $1.15 | $1.23 | +7.0% | +20.0% | +11.6% | -9.1% | -0.7% | -4.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.47 | $1.38 | -6.1% | -14.3% | +4.8% | -0.8% | -3.8% | -0.8% |
| Jun 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.13 | $1.13 | +0.0% | -3.5% | -3.7% | -2.9% | -10.8% | +2.2% |
| Jun 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.23 | $1.24 | +0.8% | -4.1% | -3.4% | -2.6% | +1.8% | -3.5% |
| Jun 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.09 | $1.12 | +2.8% | +0.9% | +1.8% | +7.1% | +6.7% | -2.3% |
| May 31 | Piper Sandler | Upgrade | Neutral → Overweight | — | $0.96 | $1.12 | +16.8% | +8.4% | +4.8% | +0.9% | +1.8% | +7.1% |
| May 30 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.13 | $1.26 | +11.5% | -15.1% | +8.4% | +4.8% | +0.9% | +1.8% |
| May 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.21 | $1.21 | +0.0% | -6.6% | -15.1% | +8.4% | +4.8% | +0.9% |
| Apr 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.71 | $0.71 | -0.3% | +11.1% | +15.0% | -0.3% | -4.0% | +1.3% |
| Feb 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.65 | $0.67 | +3.1% | +5.8% | +6.9% | +11.5% | -1.1% | +3.3% |
| May 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.45 | $0.35 | -20.9% | -15.4% | -2.9% | -9.5% | +3.6% | -4.6% |
| Mar 31 | Piper Sandler | Downgrade | Overweight → Neutral | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Mar 31 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Mar 31 | Mizuho | Downgrade | Buy → Neutral | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Mar 31 | Needham | Downgrade | Buy → Hold | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.77 | $2.88 | +4.0% | +6.5% | -2.7% | +0.0% | -1.0% | -1.4% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.41 | $3.52 | +3.2% | -2.3% | +8.1% | -2.2% | +5.7% | -3.0% |
| Jan 29 | JP Morgan | Downgrade | Neutral → Underweight | — | $3.43 | $3.36 | -2.0% | -5.5% | +5.2% | +2.6% | +12.6% | -1.8% |
| Oct 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.18 | $3.10 | -2.5% | -10.7% | -14.8% | -3.3% | -3.0% | -2.2% |
| Sep 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.65 | $2.83 | +6.8% | +2.6% | -4.4% | +1.9% | -1.9% | -2.7% |
| Sep 4 | BTIG | Maintains | Buy → Buy | — | $2.65 | $2.83 | +6.8% | +2.6% | -4.4% | +1.9% | -1.9% | -2.7% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.65 | $2.83 | +6.8% | +2.6% | -4.4% | +1.9% | -1.9% | -2.7% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.91 | $12.26 | +2.9% | +3.7% | -0.6% | +0.7% | +4.2% | -3.4% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | Mizuho | Maintains | Buy → Buy | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | JP Morgan | Maintains | Overweight → Overweight | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
No insider trades available.
8-K · 2.02
!! High
Akebia Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Akebia Therapeutics reported quarterly earnings results via press release, with the full financial details available in the furnished exhibit for investor review.
May 7
8-K
Unknown — 8-K Filing
A new director's option grant at $1.41 suggests management expects stock appreciation, but the low strike price indicates current valuation challenges that investors should monitor carefully.
Apr 1
8-K
Unknown — 8-K Filing
Q32 Bio's upcoming 36-week topline results for bempikibart in alopecia areata represent a critical near-term catalyst that could validate the drug candidate and significantly impact the stock's valuation.
Mar 10
8-K
Seres Therapeutics, Inc. -- 8-K Filing
Seres Therapeutics appointed a new executive with proven experience leading anemia programs at Akebia and managing acquisitions, strengthening its operational and clinical development capabilities.
Mar 2
8-K
Akebia Therapeutics, Inc. -- 8-K Filing
Akebia Therapeutics reports full-year 2025 results with positive early 2026 commercial momentum for its kidney disease treatment Vafseo, suggesting improved market adoption following its first-year launch.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 11,166,710 | $16M | New | Mar 2026 |
| 2 | Morgan Stanley | 2,457,632 | $4M | Reduced | Dec 2025 |
| 3 | Citigroup Inc | 2,436,203 | $4M | Added | Dec 2025 |
| 4 | Bank Of America Corp /de/ | 2,763,362 | $4M | Added | Mar 2026 |
| 5 | Qube Research & Technologies Ltd | 2,395,215 | $3M | Reduced | Mar 2026 |
| 6 | Millennium Management | 2,384,713 | $3M | Added | Mar 2026 |
| 7 | Vanguard Portfolio Management Llc | 2,215,441 | $3M | New | Mar 2026 |
| 8 | Northern Trust Corp | 1,945,586 | $3M | Reduced | Mar 2026 |
| 9 | Renaissance Technologies Llc | 1,833,128 | $3M | Reduced | Mar 2026 |
| 10 | Aqr Capital Management Llc | 1,792,620 | $2M | Added | Mar 2026 |
| 11 | Citadel Advisors Llc | 1,390,067 | $2M | Reduced | Mar 2026 |
| 12 | Acadian Asset Management Llc | 1,377,068 | $2M | Reduced | Mar 2026 |
| 13 | Fmr Llc | 1,335,328 | $2M | Added | Mar 2026 |
| 14 | Two Sigma Investments, Lp | 1,297,801 | $2M | Added | Mar 2026 |
| 15 | Hrt Financial Lp | 976,937 | $1M | Reduced | Mar 2026 |
| 16 | Connor, Clark & Lunn Investment Management Ltd. | 753,906 | $1M | Reduced | Dec 2025 |
| 17 | Jane Street Group, Llc | 691,584 | $1M | Added | Dec 2025 |
| 18 | Ubs Group Ag | 769,471 | $1M | Reduced | Mar 2026 |
| 19 | Susquehanna International Group, Llp | 722,119 | $1M | Added | Mar 2026 |
| 20 | Invesco Ltd. | 720,139 | $1M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$275.2M
Enterprise Value
$266.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.83x
P/B
8.44x
P/S
1.18x
P/FCF
4.05x
EV/EBITDA
—
Shares Out
257.2M
Financials (TTM)
Revenue
$232.4M
Net Income
-$20.5M
EBITDA
-$5.8M
Free Cash Flow
$68.0M
Op Cash Flow
$68.0M
EPS Basic
$-0.02
EPS Diluted
$-0.08
EPS Forward
$-0.06
Gross Margin
80.9%
Op Margin
2.3%
Net Margin
-8.8%
Balance Sheet
Total Assets
$376.6M
Total Liab.
$344.0M
Total Equity
$32.6M
Cash
$184.8M
LT Debt
$176.2M
Book Value/Sh
$0.13
Debt/Equity
6.63x
Current Ratio
1.13
Quick Ratio
1.04
Returns & Growth
ROE
-16.4%
ROA
-1.4%
ROIC
9.3%
Rev Growth YoY
+47.5%
EPS Growth YoY
+93.7%
Price Returns
2W
-9.7%
1M
-26.1%
3M
-22.1%
6M
-35.4%
12M
-66.3%
Technicals
52W High
$4.01
52W Low
$0.87
50d MA
$1.18
200d MA
$1.71
RSI (14)
56.10
ATR (14)
$0.07
Beta
0.37
Avg Volume
6.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$4.00
Low
$4.00
Median
$4.00
Data updated apr 24, 2026 5:05pm
· Source: financialmodelingprep.com